Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689233 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
A Phase 3 study of Alzheimers Disease, sponsored by TauRx Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 20
- Study locations
NCT01689233: Completed Phase 3 study of Alzheimers Disease, sponsored by TauRx Therapeutics.
NCT01689233 is a Phase 3 study of Alzheimers Disease that has completed, run by TauRx Therapeutics. The registered enrollment target is 800 participants, below the 3,921-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01689233, a Phase 3 study of Alzheimers Disease, has completed, sponsored by TauRx Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TRx0237 200 mg/day
Study Locations (20)
California
- CITrials - Bellflower
- ATP Clinical Research, Inc. - Costa Mesa
- Southern California Research, LLC - Fountain Valley
- Feldman, Robert MD - Laguna Hills
- Synergy East - Lemon Grove
- Collaborative Neuroscience Network - Long Beach
- Neuro-Therapeutics, Inc. - Pasadena
- Anderson Clinical Research - Redlands
- Pacific Research Network - San Diego
- San Francisco Clinical Research Center - San Francisco
- Neurological Research Institute - Santa Monica
- Schuster Medical Research Institute - Sherman Oaks
Connecticut
- Institute for Neurodegenerative Disorders - New Haven
- Coastal Connecticut Research, LLC - New London
- Research Center for Clinical Studies, Inc - Norwalk
Arizona
- Xenoscience, Inc / 21st Century Neurology - Phoenix
- NoesisPharma Clinical Trials - Phoenix
Florida
- JEM Research - Atlantis
- Bradenton Research Center - Bradenton
Colorado
- Mile High Research Center - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2012-10 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
What the finished NCT01689233 record still lists
NCT01689233 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, below the 3,921-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01689233 names 20 study sites across 5 states, led by California, Connecticut, Arizona.
Frequently Asked Questions
What is clinical trial NCT01689233 about?
NCT01689233 is a clinical study titled "Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease". The purpose of this study is to determine the safety and efficacy of TRx0237 in the treatment of subjects with mild Alzheimer's Disease.
What is the current status of trial NCT01689233?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2012-10. Estimated completion is 2016-05.
What conditions does trial NCT01689233 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT01689233?
The interventions under investigation include: Placebo (DRUG), TRx0237 200 mg/day (DRUG).
Who is sponsoring clinical trial NCT01689233?
This trial is sponsored by TauRx Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01689233 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01689233's enrollment target sits among peer trials
800 19th of 147 higher than 127 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
RECRUITING · Phase 3
-
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia